Waypoint Bio is pioneering advancements in cell therapy through its innovative platform that integrates spatial biology with high-throughput and high-dimensional multiplexing techniques. This approach addresses the traditional challenges in cell therapy development, which often involve a trade-off between the speed of in vitro methods and the quality of in vivo methods. By leveraging spatial biology technology, Waypoint Bio can measure both cell-autonomous and non-autonomous effects, allowing for a more comprehensive understanding of cellular interactions and environments. This capability enables the company to optimize cell therapy designs efficiently while maintaining in vivo relevance and quality.

The company's platform utilizes cutting-edge advancements in computer vision, in silico protein design, and pooled screening to facilitate deep phenotyping across various cell therapy designs. By employing spatial biology profiling, Waypoint Bio can rank and select the most effective cell therapies, streamlining the assessment, design, synthesis, and refinement processes. This holistic approach not only enhances the development of cell therapies but also sets a new standard in the field, promising to accelerate the delivery of innovative treatments.

United States

Waypoint's proprietary spatial multi-omics platform enables us to solve critical issues around understanding how cell therapies navigate the three-dimensional tumor microenvironment and allow the measurement of cell-to-cell interactions.

Waypoint Bio

Company Details